Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner

Kane and colleagues report a long-term NMN intervention in male and female mice. Female mice had an 8.5% increase in median lifespan, while male mice did not show a lifespan increase. Both sexes had lower frailty scores. The abstract also reports sex-specific biology: male mice showed greater physical activity, better metabolic measures and altered inflammatory pathways, while both sexes had lower abundance of the gut bacterium Anaerotruncus colihominis. The result is more informative than a short biomarker study because it includes lifespan and frailty outcomes, but it remains a preclinical preprint. The abstract does not state group sizes, dose, formulation, randomisation details, or whether survival analyses were adjusted for multiple comparisons. Sex-specific effects matter: the female lifespan result cannot be assumed to apply to males or humans. The paper supports further work on NAD+ biology, microbiome changes and biological sex, not a human NMN longevity claim. It does not change the site’s evidence grade for NMN.

These results highlight the potential of NAD+ boosters for treating age-related conditions.